Goldman Sachs’s Exagen XGN Stock Holding History

Goldman Sachs’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$364K	Buy	121,434 +39,810	+49%	+$154K	﹤0.01%	5784
2025 Q4	$496K	Buy	81,624 +19,805	+32%	+$180K	﹤0.01%	5596
2025 Q3	$679K	Buy	61,819 +39,217	+174%	+$347K	﹤0.01%	5314
2025 Q2	$158K	Buy	+22,602	New	+$137K	﹤0.01%	5722
2022 Q1	–	Sell	-10,738	Closed	-$125K	–	6942
2021 Q4	$125K	Buy	10,738 +105	+1%	+$1.23K	﹤0.01%	6075
2021 Q3	$145K	Buy	10,633 +444	+4%	+$5.9K	﹤0.01%	5832
2021 Q2	$153K	Buy	+10,189	New	+$156K	﹤0.01%	5845
2020 Q3	–	Sell	-191,978	Closed	-$2.38M	–	5563
2020 Q2	$2.38M	Buy	+191,978	New	+$2.6M	﹤0.01%	3328
2019 Q4	–	Sell	-18,000	Closed	-$279K	–	5431
2019 Q3	$279K	Buy	+18,000	New	+$291K	﹤0.01%	4712

Other funds holding XGN

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

FCM

FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

MBAM

Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return

Goldman Sachs's XGN Position: Q1 2026 in Review

Goldman Sachs increased its Exagen (XGN) stake by 49% in Q1 2026, buying an estimated $154K and bringing the position to 121,434 shares worth $364K. The position accounts for ﹤0.01% of the portfolio, ranked #5784.

Goldman Sachs first reported a position in XGN in Q3 2019 and has held it in 9 quarters since. The position peaked at $2.38M in Q2 2020. 61 funds tracked by Wall St. Rank hold XGN as of Q1 2026.

Goldman Sachs held 121,434 shares of Exagen worth $364K as of Q1 2026.
Goldman Sachs bought 39,810 Exagen shares in Q1 2026, an estimated $154K.
Exagen made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5784 holding.
Goldman Sachs first reported a position in Exagen in Q3 2019 and has held it in 9 quarters since.
Goldman Sachs's Exagen position peaked at $2.38M in Q2 2020.
61 funds tracked by Wall St. Rank held Exagen as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.